BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Babb R, Pirofski LA. Help is on the way: Monoclonal antibody therapy for multi-drug resistant bacteria. Virulence 2017;8:1055-8. [PMID: 28306387 DOI: 10.1080/21505594.2017.1306620] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zou X, Zhang Q, Lu H, Lin D, Yao S. Development of a hybrid biomimetic ligand with high selectivity and mild elution for antibody purification. Chemical Engineering Journal 2019;368:678-86. [DOI: 10.1016/j.cej.2019.03.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
2 Nielsen TB, Yan J, Luna BM, Talyansky Y, Slarve M, Bonomo RA, Spellberg B. Monoclonal antibody requires immunomodulation for efficacy against Acinetobacter baumannii infection. J Infect Dis 2021:jiab265. [PMID: 34036366 DOI: 10.1093/infdis/jiab265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Babu L, Uppalapati SR, Sripathy MH, Reddy PN. Evaluation of Recombinant Multi-Epitope Outer Membrane Protein-Based Klebsiella pneumoniae Subunit Vaccine in Mouse Model. Front Microbiol 2017;8:1805. [PMID: 28979250 DOI: 10.3389/fmicb.2017.01805] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
4 Lee IM, Tu IF, Yang FL, Wu SH. Bacteriophage Tail-Spike Proteins Enable Detection of Pseudaminic-Acid-Coated Pathogenic Bacteria and Guide the Development of Antiglycan Antibodies with Cross-Species Antibacterial Activity. J Am Chem Soc 2020;142:19446-50. [PMID: 33166120 DOI: 10.1021/jacs.0c07314] [Reference Citation Analysis]
5 Stephens LJ, Werrett MV, Sedgwick AC, Bull SD, Andrews PC. Antimicrobial innovation: a current update and perspective on the antibiotic drug development pipeline. Future Medicinal Chemistry 2020;12:2035-65. [DOI: 10.4155/fmc-2020-0225] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Kim B, Yang Q, Chan LW, Bhatia SN, Ruoslahti E, Sailor MJ. Fusogenic porous silicon nanoparticles as a broad-spectrum immunotherapy against bacterial infections. Nanoscale Horiz 2021;6:330-40. [PMID: 33599221 DOI: 10.1039/d0nh00624f] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Khan AA, Manzoor KN, Sultan A, Saeed M, Rafique M, Noushad S, Talib A, Rentschler S, Deigner HP. Pulling the Brakes on Fast and Furious Multiple Drug-Resistant (MDR) Bacteria. Int J Mol Sci 2021;22:E859. [PMID: 33467089 DOI: 10.3390/ijms22020859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Galac MR, Snesrud E, Lebreton F, Stam J, Julius M, Ong AC, Maybank R, Jones AR, Kwak YI, Hinkle K, Waterman PE, Lesho EP, Bennett JW, Mc Gann P. A Diverse Panel of Clinical Acinetobacter baumannii for Research and Development. Antimicrob Agents Chemother 2020;64:e00840-20. [PMID: 32718956 DOI: 10.1128/AAC.00840-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
9 Kawser Z, Shamsuzzaman SM. Intradermal Immunization with Heat-Killed Klebsiella pneumoniae Leading to the Production of Protective Immunoglobulin G in BALB/c Mice. Int J Appl Basic Med Res 2021;11:160-5. [PMID: 34458118 DOI: 10.4103/ijabmr.IJABMR_63_20] [Reference Citation Analysis]